Been digging into value stock screening lately and honestly the price-to-book ratio is one of those metrics everyone overlooks. Everyone talks about P/E ratios and sales multiples but P/B can actually be pretty useful if you know what you're looking at.

Basic concept: P/B ratio basically tells you if a stock is trading below what its assets are actually worth. You calculate it by dividing market cap by book value of equity. When you get a ratio under 1, theoretically the stock is cheaper than its liquidation value. Sounds simple right? But here's the thing - sometimes a low P/B just means the company is trash at making money from those assets or the assets themselves are overvalued on paper.

The real move is combining P/B screening with other metrics. You want lower P/B compared to industry peers, solid P/E ratios, decent sales multiples, and ideally analyst ratings backing it up. That's when you start finding actual opportunities.

So I looked at some stocks that fit this profile and a few caught my attention. Invesco is an interesting one - independent investment manager trading at attractive valuations with strong Zacks backing and projected 20.9% EPS growth over the next few years. Then there's Harmony Biosciences, a pharma company focused on rare neurological disorders, showing 27% projected growth which is pretty solid.

Concentrix does tech-enabled business services and while the growth is more modest at 8.76%, the valuation metrics look reasonable. Patria Investments is the Latin America private markets play - niche but the numbers suggest it could be undervalued. And Global Payments, the payments tech company, sitting at 11.54% projected growth with solid fundamentals.

The thing about using P/B as part of your screening is it works best when you're looking at asset-heavy businesses - financials, insurance, manufacturing. For tech or high-growth companies with tons of R&D spend, it's less reliable. So context matters.

If you're hunting for value plays, definitely factor price-to-book into your analysis alongside the other usual suspects. Just don't rely on it solo - that's how people get trapped in value traps. Always cross-check with earnings quality, industry comparisons, and growth prospects.